Dietary phlorizin enhances osteoblastogenic bone formation through enhancing β-catenin activity via GSK-3β inhibition in a model of senile osteoporosis

J Nutr Biochem. 2017 Nov:49:42-52. doi: 10.1016/j.jnutbio.2017.07.014. Epub 2017 Jul 28.

Abstract

Osteoporosis is one of the most prevalent forms of age-related bone diseases. Increased bone loss with advancing age has become a grave public health concern. This study examined whether phlorizin and phloretin, dihydrochalcones in apple peels, inhibited senile osteoporosis through enhancing osteoblastogenic bone formation in cell-based and aged mouse models. Submicromolar phloretin and phlorizin markedly stimulated osteoblast differentiation of MC3T3-E1 cells with increased transcription of Runx2 and osteocalcin. Senescence-accelerated resistant mouse strain prone-6 (SAMP6) mice were orally supplemented with 10 mg/kg phlorizin and phloretin daily for 12 weeks. Male senescence-accelerated resistant mouse strain R1 mice were employed as a nonosteoporotic age-matched control. Oral administration of ploretin and phorizin boosted bone mineralization in all the bones of femur, tibia and vertebra of SAMP6. In particular, phlorizin reduced serum RANKL/OPG ratio and diminished TRAP-positive osteoclasts in trabecular bones of SAMP6. Additionally, treating phlorizin to SAMP6 inhibited the osteoporotic resorption in distal femoral bones through up-regulating expression of BMP-2 and collagen-1 and decreasing production of matrix-degrading cathepsin K and MMP-9. Finally, phlorizin and phloretin antagonized GSK-3β induction and β-catenin phosphorylation in osteoblasts and aged mouse bones. Therefore, phlorizin and phloretin were potential therapeutic agents encumbering senile osteoporosis through promoting bone-forming osteoblastogenesis via modulation of GSK-3β/β-catenin-dependent signaling.

Keywords: Osteoblastogenesis; Phloretin; Phlorizin; Senile osteoporosis; Wnt signaling.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Biomarkers / metabolism
  • Bone Density
  • Bone Density Conservation Agents / adverse effects
  • Bone Density Conservation Agents / therapeutic use*
  • Bone and Bones / metabolism
  • Bone and Bones / pathology
  • Cell Line
  • Cell Survival
  • Chalcones / adverse effects
  • Chalcones / chemistry
  • Chalcones / therapeutic use
  • Dietary Supplements* / adverse effects
  • Disease Models, Animal*
  • Gene Expression Regulation, Developmental
  • Glycogen Synthase Kinase 3 beta / antagonists & inhibitors*
  • Glycogen Synthase Kinase 3 beta / genetics
  • Glycogen Synthase Kinase 3 beta / metabolism
  • Male
  • Mice
  • Osteoblasts / metabolism
  • Osteoblasts / pathology
  • Osteogenesis
  • Osteoporosis / diet therapy*
  • Osteoporosis / metabolism
  • Osteoporosis / pathology
  • Phloretin / adverse effects
  • Phloretin / therapeutic use
  • Phlorhizin / adverse effects
  • Phlorhizin / therapeutic use*
  • Specific Pathogen-Free Organisms
  • Wnt Signaling Pathway
  • beta Catenin / agonists*
  • beta Catenin / genetics
  • beta Catenin / metabolism

Substances

  • Biomarkers
  • Bone Density Conservation Agents
  • CTNNB1 protein, mouse
  • Chalcones
  • beta Catenin
  • Phlorhizin
  • Glycogen Synthase Kinase 3 beta
  • Gsk3b protein, mouse
  • dihydrochalcone
  • Phloretin